An update from Daré Bioscience ( (DARE) ) is now available.
Daré Bioscience has entered into a $15 million stock purchase agreement with Lincoln Park Capital Fund, giving Daré discretionary access to capital over a 24-month period. This agreement allows Daré to sell shares based on market conditions, aiding in funding its portfolio, including the Phase 3 study for Sildenafil Cream, a potential first-in-category treatment for female sexual arousal disorder. The deal includes provisions for share purchase limits and does not involve any warrants, penalties, or hedging by Lincoln Park, providing Daré flexibility in managing its financial strategy.
Learn more about DARE stock on TipRanks’ Stock Analysis page.
